0.6701
-0.0012 (-0.18%)
-0.0012 (-0.18%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 551,260 |
|
|||||
News | - | ||||||
Day High | 0.69 | Low High |
|||||
Day Low | 0.657 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aridis Pharmaceuticals Inc | ARDS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.69 | 0.657 | 0.69 | 0.6885 | 0.6713 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,054 | 551,260 | $ 0.6691656 | $ 368,884 | - | 0.5722 - 2.94 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:58:32 | 5 | $ 0.6846 | USD |
Aridis Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 17.40M | 25.97M | 24.53M | $ - | $ - | -3.65 | -0.40 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 122.00k | 5.60% |
Aridis Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARDS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.7564 | 0.77989 | 0.6026 | 0.6912358 | 1,508,337 | -0.0863 | -11.41% |
1 Month | 1.46 | 1.49 | 0.5722 | 0.993698 | 2,528,415 | -0.7899 | -54.1% |
3 Months | 0.82 | 1.7458 | 0.5722 | 0.9997584 | 910,837 | -0.1499 | -18.28% |
6 Months | 2.10 | 2.39 | 0.5722 | 1.02 | 489,302 | -1.43 | -68.09% |
1 Year | 2.05 | 2.94 | 0.5722 | 1.37 | 369,407 | -1.38 | -67.31% |
3 Years | 6.98 | 10.18 | 0.5722 | 2.17 | 317,714 | -6.31 | -90.4% |
5 Years | 13.02 | 13.85 | 0.5722 | 2.29 | 218,293 | -12.35 | -94.85% |
Aridis Pharmaceuticals Description
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. |